LIXISENATIDE SANOFI lixisenatide 20 mcg (0.1 mg/mL) solution for injection injector pen Australia - English - Department of Health (Therapeutic Goods Administration)

lixisenatide sanofi lixisenatide 20 mcg (0.1 mg/ml) solution for injection injector pen

sanofi-aventis australia pty ltd - lixisenatide -

LIXISENATIDE SANOFI lixisenatide 10 mcg (0.05mg/mL) solution for injection injector pen Australia - English - Department of Health (Therapeutic Goods Administration)

lixisenatide sanofi lixisenatide 10 mcg (0.05mg/ml) solution for injection injector pen

sanofi-aventis australia pty ltd - lixisenatide -

LIXISENATIDE WINTHROP lixisenatide 20 mcg (0.1 mg/mL) solution for injection injector pen Australia - English - Department of Health (Therapeutic Goods Administration)

lixisenatide winthrop lixisenatide 20 mcg (0.1 mg/ml) solution for injection injector pen

sanofi-aventis australia pty ltd - lixisenatide -

LIXISENATIDE WINTHROP lixisenatide 10 mcg (0.05mg/mL) solution for injection injector pen Australia - English - Department of Health (Therapeutic Goods Administration)

lixisenatide winthrop lixisenatide 10 mcg (0.05mg/ml) solution for injection injector pen

sanofi-aventis australia pty ltd - lixisenatide -

ADLYXIN- lixisenatide kit ADLYXIN- lixisenatide injection, solution United States - English - NLM (National Library of Medicine)

adlyxin- lixisenatide kit adlyxin- lixisenatide injection, solution

sanofi-aventis u.s. llc - lixisenatide (unii: 74o62bb01u) (lixisenatide - unii:74o62bb01u) - lixisenatide 50 ug in 1 ml - adlyxin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use : - adlyxin has not been studied in patients with chronic pancreatitis or a history of unexplained pancreatitis. consider other antidiabetic therapies in patients with a history of pancreatitis [see warnings and precautions (5.2)] . - adlyxin should not be used in patients with type 1 diabetes mellitus. - adlyxin has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis. adlyxin is contraindicated in patients with known severe hypersensitivity to lixisenatide or to any component of adlyxin. hypersensitivity reactions including anaphylaxis have occurred with adlyxin [see warnings and precautions (5.1)and adverse reactions (6.1)] . risk summary the limited available data with lixisenatide in pregnant women are not sufficient to inform a drug-associated risk of major birth defects a

LIXISENATIDE SANOFI TREATMENT INITIATION PACK 10mcg (0.05 mg/mL) and 20 mcg (0.1) mg/mL solution for injection injector pen Australia - English - Department of Health (Therapeutic Goods Administration)

lixisenatide sanofi treatment initiation pack 10mcg (0.05 mg/ml) and 20 mcg (0.1) mg/ml solution for injection injector pen

sanofi-aventis australia pty ltd - lixisenatide -

LIXISENATIDE WINTHROP TREATMENT INITIATION PACK 10mcg (0.05 mg/mL) and 20 mcg (0.1) mg/mL solution for injection injector pen Australia - English - Department of Health (Therapeutic Goods Administration)

lixisenatide winthrop treatment initiation pack 10mcg (0.05 mg/ml) and 20 mcg (0.1) mg/ml solution for injection injector pen

sanofi-aventis australia pty ltd - lixisenatide -

LIXISENATIDE SANOFI Australia - English - Department of Health (Therapeutic Goods Administration)

lixisenatide sanofi

sanofi-aventis australia pty ltd - lixisenatide -

LIXISENATIDE WINTHROP Australia - English - Department of Health (Therapeutic Goods Administration)

lixisenatide winthrop

sanofi-aventis australia pty ltd - lixisenatide -

LYXUMIA lixisenatide 10 mcg (0.05mg/mL) solution for injection injector pen Australia - English - Department of Health (Therapeutic Goods Administration)

lyxumia lixisenatide 10 mcg (0.05mg/ml) solution for injection injector pen

sanofi-aventis australia pty ltd - lixisenatide -